Harmony Biosciences Holdings, Inc. (HRMY)

Market Cap	1.97B
Revenue (ttm)	681.88M
Net Income (ttm)	122.63M
Shares Out	57.03M
EPS (ttm)	2.11
PE Ratio	16.41
Forward PE	11.17
Dividend	n/a
Ex-Dividend Date	n/a

Volume	599,896
Open	35.14
Previous Close	34.89
Day's Range	33.97 - 35.27
52-Week Range	28.14 - 41.61
Beta	0.79
Analysts	Strong Buy
Price Target	54.38 (+57.35%)
Earnings Date	Feb 25, 2025

About HRMY

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Har...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Aug 19, 2020
• Employees: 246
• Stock Exchange: NASDAQ
• Ticker Symbol: HRMY
• Website: https://www.harmonybiosciences.com

Financial Performance

In 2023, HRMY's revenue was $582.02 million, an increase of 32.93% compared to the previous year's $437.86 million. Earnings were $128.85 million, a decrease of -28.99%.

Analyst Forecast

According to 8 analysts, the average rating for HRMY stock is "Strong Buy." The 12-month stock price forecast is $54.38, which is an increase of 57.35% from the latest price.

Price Target

$54.38

(57.35% upside)

Analyst Consensus: Strong Buy